peginesatide acetate · Takeda Pharms Usa · NDA 202799
Omontys
Earliest generic entry, as listed · earliest of 2 marketed strengths
Open now
No marketed reference-listed strength; date taken from all listed strengths.
No unexpired patents or exclusivities are listed for this product.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 202799 · 007 · discontinued | solution, intravenous, subcutaneous | EQ 10MG BASE/ML (EQ 10MG BASE/ML) | open |
| 202799 · 008 · discontinued | solution, intravenous, subcutaneous | EQ 20MG BASE/2ML (EQ 10MG BASE/ML) | open |
Expired or delisted (2)
- US 7550433 · use U-1238 · 2 Jun 2026
- US 7919461 · use U-1238 · 2 Jun 2026